Search

Anavex Life Sciences Corp

Closed

SectorHealthcare

2.41 2.55

Overview

Share price change

24h

Current

Min

2.31

Max

2.43

Key metrics

By Trading Economics

Income

14M

7.8M

EPS

0.08

Employees

34

EBITDA

3.3M

-3.2M

Dividends

By Acuity

Next Earnings

24 lis 2026

Market Stats

By TradingEconomics

Market Cap

-47M

241M

Previous open

-0.14

Previous close

2.41

News Sentiment

By Acuity

41%

59%

103 / 339 Ranking in Healthcare

Anavex Life Sciences Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 wrz 2026, 19:46 UTC

Anavex Life Sciences Corp shares fell sharply, continuing an eight-session decline and reaching a new low, remaining well below the 20-day moving average.

15 wrz 2026, 20:03 UTC

News

Anavex Life Sciences Corp shares declined as PVG Asset Management criticized the board's governance, urging shareholders to support their nominees amid perceived failures.

10 wrz 2026, 20:07 UTC

News

Anavex Life Sciences shares are lower as PVG Asset Management plans a proxy campaign to change the board, citing concerns over governance and leadership.

9 wrz 2026, 19:46 UTC

News

Anavex Life Sciences shares decline as PVG Asset Management calls for a board replacement, citing concerns over inexperience and funding issues for upcoming trials.

8 wrz 2026, 20:21 UTC

Anavex Life Sciences Corp shares are lower in after-market trading, declining significantly below the 20-day moving average and near the lower end of its one-month range.

4 wrz 2026, 19:46 UTC

News

Anavex Life Sciences is rising as PVG Asset Management proposes changes to its Board of Directors, aiming to enhance governance and accountability.

3 wrz 2026, 19:46 UTC

News

Anavex Life Sciences has regained Nasdaq compliance but shares are lower. The stock remains below its 20-day moving average amid broader market sentiment.

2 wrz 2026, 21:01 UTC

News

Anavex Life Sciences regained compliance with Nasdaq rules after filing overdue reports. Shares are lower in after-market trading, reflecting broader market dynamics.

1 wrz 2026, 19:54 UTC

Anavex Life Sciences Corp shares are trading higher today, recovering from an early dip amid broader market pressures and rising Treasury yields.

31 sie 2026, 21:01 UTC

Anavex Life Sciences Corp is trading higher in after-market hours, rebounding from earlier lows after five sessions of declines.

28 sie 2026, 19:16 UTC

Anavex Life Sciences Corp. shares are lower today, extending a three-session decline amid broader market concerns over inflation and corporate growth expectations.

27 sie 2026, 22:01 UTC

Anavex Life Sciences Corp is rising in after-hours trading, continuing a gradual ascent since Thursday's close, despite broader market conditions and no specific news.

26 sie 2026, 23:41 UTC

Anavex Life Sciences Corp shares are higher during after-market hours, supported by a broader market trend. No specific company news was identified.

25 sie 2026, 20:07 UTC

Event
News

Anavex Life Sciences reported Q3 2026 net income of $7.8 million, returning to profitability. Shares are trading higher following the financial results and pipeline updates.

24 sie 2026, 23:11 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, building on positive momentum from Monday's close and a strong one-month performance.

21 sie 2026, 20:06 UTC

Anavex Life Sciences Corp is gaining amid broader market strength, reflecting a robust performance in biotechnology and positive investor sentiment despite no specific company news.

20 sie 2026, 20:01 UTC

Anavex Life Sciences Corp shares are lower today, driven by significant weakness in the Biotechnology sub-sector and broader trends affecting the sector.

19 sie 2026, 19:44 UTC

Anavex Life Sciences Corp is trading sharply higher, reaching a session high and maintaining a position above its 20-day moving average. No specific news was identified.

17 sie 2026, 19:46 UTC

News

Anavex Life Sciences has communicated with stockholders about director nominees amid a "Hold" rating from analysts. Shares are trading roughly flat since Friday's close.

14 sie 2026, 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

13 sie 2026, 22:51 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, continuing a trend of declines over three consecutive sessions. No specific news was identified.

12 sie 2026, 19:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Tuesday's close, despite remaining above the 20-day moving average.

11 sie 2026, 23:22 UTC

Anavex Life Sciences Corp is trading lower in after-market hours with no specific news. The stock remains well above its 20-day moving average.

10 sie 2026, 19:46 UTC

Anavex Life Sciences is trading higher today, despite no specific news. Broader market sentiment is influenced by upcoming inflation data and Fed policy expectations.

7 sie 2026, 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

6 sie 2026, 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

5 sie 2026, 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

4 sie 2026, 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

3 sie 2026, 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 lip 2026, 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

Peer Comparison

Price change

Anavex Life Sciences Corp Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Sentiment

By Acuity

103 / 339 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Interest expense on debt

EBITDA

Operating profit

$

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat